Bronchial Spasm - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The bronchial spasm market size was valued at USD 4.25 billion in 2025 and is estimated to grow from USD 4.52 billion in 2026 to reach USD 6.16 billion by 2031, at a CAGR of 6.40% during the forecast period (2026-2031). This report is segmented by Treatment (Bronchodilators, Anticholinergics, Corticosteroids, Combination Therapies, Others), Route of Administration (Inhalational, Oral, Intravenous), Patient Age (Pediatric, Adult, Geriatric), End User (Hospitals, Specialty Clinics, Homecare Settings, Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts are in Value (USD).

Global Bronchial Spasm Market Trends and Insights

Rising Asthma and COPD Burden Creates a Durable Demand Floor

The bronchial spasm market benefits from sustained demand for long-term respiratory treatment. The World Health Organization stated in 2025 that more than 250 million people lived with asthma worldwide. Essential inhaled medicines remained unavailable in more than two-thirds of pharmacies and hospitals in low- and middle-income countries, limiting treatment access. Improved case finding and disease registries can expand the treated patient base, while the WHO European Region reported that global COPD cases are projected to increase by 23% between 2020 and 2050.

Shift Toward Combination and Long-Acting Bronchodilator Therapy Lifts Average Revenue Per Patient

The bronchial spasm market is shifting toward combination therapies for patients requiring stronger symptom control. The KALOS and LOGOS Phase 3 trials, published in February 2026, showed that budesonide, glycopyrronium, and formoterol improved trough FEV1 by 76 mL versus dual ICS-LABA therapy and reduced severe exacerbations by 14%. The American College of Chest Physicians issued a guideline on biologic management in severe asthma in January 2026, supporting structured treatment-switching decisions. These developments strengthen the commercial value of single-inhaler therapies that integrate medicines, device design, and clinical evidence.

Inhaler-Use Errors and Treatment-Adherence Gaps Suppress Therapeutic Outcomes

Inhaler technique errors and adherence gaps remained material constraints for the bronchial spasm market. A 2025 review of connected inhaler data found that high reliever use predicted COPD exacerbations, although routine care often missed these indicators. Incorrect use reduced the effectiveness of controller and rescue medicines, even when prescriptions were filled, leading to avoidable acute care utilization. Manufacturers and providers must support medicine access with patient education, device guidance, and appropriate follow-up.

Other drivers and restraints analyzed in the detailed report include:

• Increasing Diagnosis of Severe and Eosinophilic Asthma Redefines Market Ceiling
• Greater Use of Connected Inhalers and Home-Based Respiratory Care Reshapes Adherence Economics
• Unequal Availability of Essential Inhaled Medicines Caps Geographic Expansion

Segment Analysis

Bronchodilators held 52.56% of total treatment revenue in 2025, supported by their broad use in rapid symptom relief and long-term maintenance. Short-acting beta-2 agonists remain critical for acute bronchospasm management, while long-acting beta-2 agonists support maintenance regimens. Anticholinergics maintain an established role, particularly for COPD-associated bronchospasm. This broad treatment base drives demand across primary care, specialist care, and acute-care settings.

Corticosteroids are the fastest-growing treatment category, with this segment projected to expand at a 9.15% CAGR through 2031. Growth is supported by greater recognition of eosinophilic and T2-high asthma and the use of inhaled corticosteroids with targeted add-on therapies. The 2025 CHEST guideline issued by the American College of Chest Physicians includes anti-IL-5 therapies and IL-4 receptor antagonists for severe asthma management. Combination inhalers and biologics also increase the importance of clinical evidence, eligibility testing, and reimbursement support.

Inhalational delivery accounted for 47.76% of total treatment revenue in 2025, supported by rapid onset and direct pulmonary delivery. Metered-dose inhalers and dry-powder inhalers remain the leading device formats. GSK stated that 300 million salbutamol metered-dose inhalers are dispensed each year globally. Manufacturers are also reducing the environmental impact of inhaler propellants. AstraZeneca received approval in 2025 for Trixeo Aerosphere in the United Kingdom using HFO-1234ze(E), a propellant with 99.9% lower global warming potential than current propellants.

Oral administration is projected to grow at an 8.80% CAGR through 2031, the fastest rate among routes in the bronchial spasm market. Demand is increasing for systemic treatments that target inflammatory pathways not addressed by inhaled therapies. Injectable biologics, included within this route category, are changing the treatment mix for severe asthma. Intravenous administration remains relevant in emergency and hospital settings, while nebulizer performance and aerosol quality standards continue to influence hospital purchasing decisions and device specifications.

Complete Report Scope:

• By Treatment
  • Bronchodilators
    • Short-Acting Beta-2 Agonists
    • Long-Acting Beta-2 Agonists
  • Anticholinergics
  • Corticosteroids
  • Combination Therapies
  • Others
• By Route of Administration
  • Inhalational Administration
  • Oral Administration
  • Intravenous Administration
• By Patient Age
  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients
• By End User
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Ambulatory Surgical Centers
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.44% of total treatment revenue in 2025, making it the largest regional contributor. The United States had 27 million asthma patients and nearly 10 million asthma attacks annually. AstraZeneca launched BREZTRI Aerosphere for asthma in the United States in July 2026, following FDA approval on April 28, 2026. Chiesi’s TRIMBOW was approved for the maintenance treatment of asthma in adults in May 2026.

Europe was the second-largest region in the bronchial spasm market. Its healthcare systems provided broad access to respiratory treatments, although tendering and generic substitution pressured originator prices. The WHO European Region reported USD 20.7 billion in productivity losses from chronic respiratory diseases among people aged 30-74 years. Chiesi received European Commission authorization for its NEXThaler single-inhaler triple therapy for adults with asthma on July 31, 2026. Germany, the United Kingdom, France, Italy, and Spain accounted for a significant share of the region’s treatment volume.

Asia-Pacific is forecast to expand at a CAGR of 10.88% through 2031, the fastest growth rate in the bronchial spasm market. China and India are central to this growth due to their substantial respiratory disease burden. GSK’s Trelegy Ellipta received approval from China’s National Medical Products Administration for adult asthma on January 23, 2026. GSK stated that China had 46 million adults with asthma. India’s Jan Aushadhi program is expanding access to lower-cost inhalers, while Brazil’s 2025 public-system decisions and Chile’s December 2025 biologic coverage under GES broadened access in South America.

List of Companies Covered in this Report:

• Amphastar Pharmaceuticals
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• Dr. Reddy’s Laboratories
• GlaxoSmithKline
• Hikma Pharmaceuticals
• Lupin
• Merck
• Nephron Pharmaceuticals Corporation
• Novartis
• Organon
• Pfizer
• Sandoz Group AG
• Sanofi
• Sun Pharmaceuticals Industries
• Teva Pharmaceutical Industries
• Viatris
• Zydus Lifesciences Limited

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support